Introduction
TGF-b has been characterized as a well-known regulator of hematopoiesis through detailed studies of hematopoietic progenitors in vitro. A relatively recent detailed review describes how TGF-b regulates proliferation and differentiation of hematopoietic precursors in vitro, often as a negative regulator of proliferation . In this review, we will discuss how various Smad signaling pathways (TGF-b, bone morphogenetic protein (BMP), activin) regulate hematopoiesis in vitro and in vivo. Smad signaling participates in the specification or generation of hematopoietic stem cells (HSCs) during development and continues to regulate the fate of HSCs and their progeny after their generation during development and postnatally. We will discuss how genetic approaches using gain-of-function or lack-of-function animal models can be used to investigate the role of Smad signaling in vivo and how the findings obtained compare with earlier in vitro findings using active ligands. The outcome of Smad signaling is very context dependent and will often have a different effect in ex vivo cultures than in the bone marrow (BM) microenvironment where many internal and external signals cooperate to regulate the fate of HSCs and their progeny. The importance of signaling crosstalk will be discussed as well as how the knowledge generated can be used in clinical medicine, for example, by expanding stem cells for advanced cell therapy in the future.
Ligands and receptors that activate Smad signaling pathways
TGF-b is the founding member and prototype of a large superfamily of structurally related peptide growth factors. Other key members of this TGF-b superfamily are the activins, BMPs and growth and differentiation factors (Massague, 1998) . There are three isoforms of TGF-b in mammals, TGF-b1 (Derynck et al., 1985) , TGF-b2 (de Martin et al., 1987; Madisen et al., 1988) and TGF-b3 (Derynck et al., 1988; ten Dijke et al., 1988) , which are encoded by separate genes located at different chromosomes. These isoforms share 70-80% amino-acid sequence identity, bind to the same receptors and show very similar actions in in vitro culture systems. However, they have distinct expression patterns in vivo and mice lacking either TGF-b1, 2 or 3 overlap phenotypically very little, indicating that there are many specific functions for the different isoforms (see below).
Members of the TGF-b superfamily transduce their signals across the plasma membrane through transmembrane serine/threonine kinase receptors. Ligand binding to these signaling receptors is facilitated by certain accessory receptors, for example, betaglycan and endoglin, which have affinity for the ligand but no signaling activity (Cheifetz et al., 1992; Lopez-Casillas et al., 1993) . There are two classes of signaling receptors, type I and type II, both of which are required for signal transduction (reviewed in Massague, 1998) . Type I receptors, also known as activin receptor-like kinases (ALKs), have an inactive kinase domain, while type II receptor kinases are constitutively active. The ligand binds constitutively active type II receptors, whereby the inactive type I receptors are recruited to form a heterotetrameric complex in which the type II receptor transphosphorylates and activates the kinase domain of the type I receptor (Wrana et al., 1994) . Activated type I receptor kinase subsequently phosphorylates intracellular mediators known as the Smad proteins (Figure 1) .
The activation of the receptors is tightly regulated through ligand traps, soluble proteins that sequester the ligand and block its access to membrane receptors. These include the TGF-b latency-associated polypeptide, decorin and a2-macroglobulin, which bind to free TGF-b, and follistatin, which binds to activins and BMPs (Shi and Massague, 2003) . The regulation of receptor activation is also controlled by membraneanchored proteins that act as coreceptors and promote ligand binding to the signaling receptors. Betaglycan, often referred to as the TGF-b type III receptor, promotes high-affinity presentation of TGF-b to the signaling receptor and this is particularly critical for TGF-b2 (Derynck and Zhang, 2003; Shi and Massague, 2003) . Betaglycan also facilitates the binding of inhibin to activin receptors to block activin signaling. Endoglin is another membrane-anchored protein, structurally related to betaglycan, which facilitates TGF-b signaling in endothelial cells (ECs). Although endoglin does not bind TGF-b by itself, mutations in endoglin and the ALK1 receptor can give rise to hereditary hemorrhagic telangiectasia (HHT), indicating a common role for endoglin and ALK1 in maintaining normal vascular development. More recently, a role for endoglin in hematopoiesis has been suggested because endoglin is expressed on HSCs (Chen et al., 2002) . Antibodies against endoglin can be used to highly enrich repopulating HSCs by flow cytometry, sorting cells that are endoglin positive, Sca-1 þ and Rhodamine-low (Chen et al., 2003) . The role of endoglin, if any, in the regulation of HSCs is unknown.
Smad signaling pathways that regulate hematopoiesis
The Smad proteins can be divided into three different groups depending on their role in the signal transduction: the receptor-activated Smads (R-Smads), the common-partner Smad (Smad4) and the inhibitory Smads (I-Smads) . R-Smads become phosphorylated by activated type I receptors, whereby they oligomerize with Smad4 to form a heterodimeric complex that is translocated into the nucleus (Figure 1 ). R-Smad/Smad4 complexes have been shown to interact directly with specific DNA sequences as well as with transcription factors, coactivators and corepressors to regulate transcription of target genes in a cell-typespecific and ligand dose-dependent manner Derynck and Zhang, 2003; ten Dijke and Hill, 2004) . R-Smads and Smad4 bind to specific DNA sequences with a 100-fold lower affinity than the interacting high-affinity, DNA-binding transcription factors, yet their DNA binding (except Smad2) is required for transcriptional activation (Derynck and Zhang, 2003) . The I-Smads act as inhibitors of Smadmediated signal transduction by interacting with the type I receptor and inhibiting the phosphorylation of R-Smads (Nakao et al., 1997) (Shi and Massague, 2003; ten Dijke and Hill, 2004) . Alternatively, I-Smads may compete with Smad4 in binding R-Smads and thereby prevent the formation of the R-Smad/Smad4 complex (Hata et al., 1998) . Figure 1 describes the close relationship between the TGF-b, activin and BMP signaling pathways. TGF-b signals through specific type I and type II receptors known as TbRI (or ALK5) and TbRII, respectively (Wang et al., 1991; Attisano et al., 1993; Ebner et al., 1993; Franzen et al., 1993) . The activated TGF-b receptor complex phosphorylates the R-Smads Smad2 and Smad3, which also act as mediators of the activin signaling pathway . In addition to signaling via ALK5, it has been shown that TGF-b can signal through another type I receptor (ALK1) in ECs, which phosphorylates a different set of R-Smads: Smad1, Smad5 and Smad8 (Roelen et al., 1997; Lux et al., 1999; Oh et al., 2000) . These Smads are the intracellular mediators of the BMP signaling pathway. As shown in Figure 1 , the type I receptors ALK1, ALK2 (ActRI), ALK3 (BMPRIA) and ALK6 (BMPRIB) phosphorylate Smad1, Smad5 and Smad8, whereas ALK4 (ActRIB) and ALK5 (TGF-bRI) phosphorylate Smad2 and Smad3 (Derynck and Zhang, 2003; Shi and Massague, 2003; ten Dijke and Hill, 2004) . All R-Smads from both the activin and BMP groups use Smad4 as a partner to form a transcriptionally active complex. The I-Smad, Smad7 inhibits the activity of all R-Smads, while Smad6 shows a more preferential inhibition of the BMP Smads (Itoh et al., 1998) .
Specificity of signaling
This convergence in the mediation of signals from TGFb superfamily members by using the Smad pathway raises the question of how specificity in signaling for different family members and different isoforms can be achieved. As mentioned above, expression of accessory proteins like betaglycan and endoglin can affect signaling specificity. Different combinations of receptor molecules in the tetrameric receptor complexes allow differential ligand binding and a differential signal response. For example, activin receptor type II combines with ALK4 to mediate activin signals, but when it combines with ALK3 or ALK6, it mediates signals from BMP4 (Derynck and Zhang, 2003; Shi and Massague, 2003) . Heteromeric interactions of activated Smads may also determine signaling specificity. Most TGF-b responses are mediated by Smad3 and Smad4, whereas activin responses are mediated by Smad2 and Smad4 (Derynck and Zhang, 2003) . Some TGF-b responses require a concomitant activation of Smad2 and Smad3 together with Smad4 (Feng et al., 2000) . The cellular context is also very important in determining the consequences of Smad signaling responses since different cells express a variety of transcription factors and cofactors to determine whether a specific set of genes can be affected, activated or repressed. For example, Smad3 cooperates with Runx proteins to activate transcription in epithelial cells, whereas the same promoters in mesenchymal cells are repressed (Alliston et al., 2001; Derynck and Zhang, 2003) .
Duration and intensity of the signal
Upon signal stimulation, Smad complexes accumulate in the nucleus where they remain for hours (ten Dijke and Hill, 2004) . The levels of the Smad complexes in the nucleus determine the nature and the duration of the signal. In the nucleus, the R-Smads are dephosphorylated and are disassociated from Smad4 and exported from the nucleus. If the receptors are active, Smad signaling continues, but if the receptors are inactive, the dephosphorylated Smads accumulate over time in the cytoplasm and signaling stops (Inman et al., 2002; Xu et al., 2002) . Apart from nucleocytoplasmic shuttling of Smads, the duration and activity of Smad pathways can be regulated by different receptor internalization routes. Clathrindependent internalization of receptors into early endosomes promotes Smad signaling, whereas internalization via lipid raft-caveolar compartments containing receptor bound to Smad7-ubiquitin ligase complexes leads to degradation of receptors (Di Guglielmo et al., 2003; Shi and Massague, 2003; ten Dijke and Hill, 2004) . Therefore, the internalization pathway has implications for receptor availability and duration of the signal.
Smad-dependent and Smad-independent signaling crosstalk with other pathways Smads are the most well-characterized transducers of TGF-b signaling so far, playing a critical role in most TGF-b actions. Increasing evidence suggests, however, that TGF-b may also send signals though another intracellular signaling pathway, the mitogen-activated protein kinase (MAPK) pathway (reviewed in Massague, 2000) . The complexity of intracellular TGF-b signal transduction is further demonstrated by the fact that the Smad pathway is believed to be part of a larger network involving many other signaling pathways, which are interacting in a so-called 'signaling crosstalk' (Massague, 2000) . Several kinase pathways inhibit or enhance TGF-b-induced nuclear translocation of Smads. For example, the Erk MAPK pathway, stimulated by the activation of tyrosine kinase receptors and/or Ras, inhibits ligand-induced nuclear translocation of activated Smads (de Caestecker et al., 1998; Kretzschmar et al., 1999; Funaba et al., 2002; Derynck and Zhang, 2003) . The Erk MAPK and calciumcalmodulin-dependent protein kinase II inhibit TGF-b signaling through phosphorylation of Smads at phosphorylation sites that are different from those that are phosphorylated by ALKs (Derynck and Zhang, 2003; Shi and Massague, 2003) . TGF-b signaling can also be independent of the Smad pathways (reviewed in Derynck and Zhang, 2003) . Rapid activation (5-15 min) by TGF-b does not involve Smad-mediated trans-criptional responses and independence from Smad activation has been supported by findings demonstrating MAPK activation in Smad4-deficient cells and cells that express dominant-negative Smads (Engel et al., 1999) . Therefore, MAPK pathways can regulate Smad transcriptional responses, but TGF-b can also activate Erk, JNK (c-Jun N-terminal kinase) and p38 MAPK kinase pathways independent of Smad-mediated transcription. This complex crosstalk by TGF-b family of ligands with other signaling cascades has also been extended to other signaling pathways (reviewed in Derynck and Zhang, 2003) .
Hematopoiesis and HSCs
All blood cells can be generated from a common HSC through an extremely dynamic process called hematopoiesis or blood cell formation. The generation of definitive or adult-type HSC during development occurs in the aorta-mesonephros-gonad region (AGM) of the embryo (Medvinsky et al., 1993; Cumano et al., 1996; Medvinsky and Dzierzak, 1996; Cumano et al., 2000) , and more recently there have been reports that may indicate that definitive HSC are also found in the yolk sac and later in placenta (Yoder et al., 1997; Gekas et al., 2005) . The fetal liver is seeded with HSC from the AGM and they are expanded there and generate a large amount of progeny cells. Postnatally, hematopoiesis takes place in the BM where the HSCs as well as a complex mix of dividing and maturing cells of different lineages can be found. The process of hematopoiesis can be described as hierarchical with the rare HSCs at the top of the hierarchy giving rise first to progenitors and then to precursors with single lineage commitment and ending in terminally differentiated mature cells of various lineages (Ogawa, 1993; Orkin, 2000) . In between the HSC and terminally differentiated cells, there is a continuum of progenitors at different stages, which, depending on certain stimuli, can divide and progress towards certain lineages (Figure 2) . It is generally believed that hematopoietic development divides at an early stage into a myeloid and a lymphoid branch. The lymphoid branch gives rise to B, T and natural killer cells, while the myeloid branch differentiates to all other cell types including erythrocytes. Indeed, two distinct progenitor populations with either lymphoid or myeloid restricted potential, the so-called common lymphoid progenitors and common myeloid progenitors, have been isolated from mouse BM (Kondo et al., 1997; Akashi et al., 2000) .
HSCs are pluripotent and should therefore be able to give rise to all hematopoietic lineages. They are operationally defined as cells that can completely reconstitute a recipient following BM ablation. Similarly, they must have the capacity to self-renew to give rise to other stem cells (Domen and Weissman, 1999) . A distinction is often made between long-term repopulating HSCs (LT-HSCs) and short-term repopulating HSCs (ST-HSCs) (Morrison and Weissman, 1994) . The only way to test these criteria is through BM transplantation experiments into lethally irradiated recipients. Although the HSC can only be absolutely defined through BM transplantation assays, advances in cell sorting have allowed near purification of murine HSC. Early committed progenitor populations, depicted in Figure 2 , can also be purified (Spangrude et al., 1988; Morrison and Weissman, 1994; Kondo et al., 1997; Akashi et al., 2000) . HSC are highly enriched in a population that is negative for lineage markers (Lin À ) and positive for Sca-1 and c-kit (LSK cells) (Spangrude et al., 1988) . C-kit, which is the receptor for stem cell factor (SCF), has a wider expression pattern than Sca-1, marking most multipotent progenitors (MPPs) (Lyman and Jacobsen, 1998 (Osawa et al., 1996) . A further separation between LT-HSC, ST-HSC and MPP has recently been made by showing that repopulating HSC express the thrombopoietin (Tpo) receptor (c-mpl), whereas MPP do not, and MPPs express Flt3, whereas pluripotent repopulating HSC do not Yang et al., 2005a) .
Regulation of hematopoiesis
Regulation of HSCs is governed by two intimately involved entities. One is the gene expression pattern in the cell and the other is the composition of external signals from the BM microenvironment. Transcription factors are internal signals that regulate gene expression, while external signals from the BM microenvironment can be mediated by cell-cell interactions, cell-extracellular matrix (ECM) interactions and by soluble growth factors. Figure 3 demonstrates the various fate options upon alteration of internal or external signals that may promote or antagonize proliferation (selfrenewal), quiescence, differentiation, migration, apoptosis or malignant transformation.
A number of transcription factors have been shown to be critical intrinsic factors for specification of HSCs during ontogeny. Nascent HSC in the AGM region express the hematopoietic transcription factors Runx-1, c-Myb, PU.1, SCL and LMO2 (Tavian et al., 1996; North et al., 1999; Orkin and Zon, 2002) . Most of these genes have also been found to be essential for hematopoiesis using mouse knockout models. They are also observed in chromosomal translocations in leukemias or cause leukemia when misexpressed or disrupted in the mouse (reviewed in Orkin, 2000) . Studies in knockout mouse models have elegantly demonstrated crucial roles of several transcription factors in early hematopoietic commitment steps and lineage outcome. For example, GATA-1 is required for erythroid and megakaryocytic development and Pax-5 for B-cell development (Pevny et al., 1991; Fujiwara et al., 1996; Shivdasani et al., 1997; Nutt et al., 1999; Rolink et al., 1999) . The PU.1 and GATA-1 transcription factors have both been shown to have concentration-dependent effects on differentiation and lineage choice (Kulessa et al., 1995; DeKoter and Singh, 2000) . Enforced expression of HoxB4 has been shown to increase the self-renewal potential of primitive murine and human hematopoietic progenitors (Sauvageau et al., 1995; Antonchuk et al., 2002; Buske et al., 2002) and deficiency of HoxB4 causes a mild proliferative defect in HSC Brun et al., 2004) . Apart from transcription factors, there are also other intrinsic factors within the HSCs that are important regulators of stem cell fate. These include effector molecules in the cell cycle machinery. For example, high levels of cyclin D2 have been detected in cycling HSCs, suggesting an important role in HSC cycling, while studies of knockout mice have shown that the cyclin-dependent kinase inhibitor (CDKI) p21 acts to maintain HSCs in a quiescent state (Cheshier et al., 1999; Cheng et al., 2000) .
Many hematopoietic growth factors have been considered to be key external regulators of HSCs. SCF (also known as c-kit ligand) and its receptor c-kit as well as Tpo and its receptor c-mpl are expressed on HSCs and efficiently promote survival of primitive murine and human primitive progenitors (Li and Johnson, 1994; Keller et al., 1995; Borge et al., 1996) . They can also synergize with other growth factors, such as IL-3 and IL-6, to induce proliferation of these primitive cells and are therefore widely used in various in vitro culture systems . Important roles in HSC regulation in vivo have been shown through analysis of mice lacking either c-kit or c-mpl. These mice have severe HSC deficiencies as demonstrated by reduced LT repopulating ability following transplantation (Miller et al., 1996; Kimura et al., 1998) . Flt3-ligand (FL) and its receptor Flt3 has been shown to promote in vitro growth of HSCs (Lyman and Jacobsen, 1998). However, a role of FL in regulating the most primitive HSCs is uncertain since Flt3 is not expressed on LTR-HSCs . Stem cell homeostasis in the adult may also be under control of morphogens that regulate early embryogenesis (Orkin and Zon, 2002) . BMP4 maintains HSC in culture and sonic hedgehog (Shh) may amplify HSC through modulation of the BMP pathway (Bhatia et al., 1999; Bhardwaj et al., 2001) . The Notch signaling pathway and the Wnt pathway also regulate HSC homeostasis and both activation of Notch and stimulation by Wnt have been shown to increase proliferation of HSC Varnum-Finney et al., 2000; Stier et al., 2002; Reya et al., 2003) .
It is generally believed that maintenance of HSCs is controlled by a balance of positively and negatively acting signals. Although a number of growth factors have been identified that exert critical growth promoting effects on HSCs, as described above, much less is known about negative regulation of HSCs. Apart from TGF-b (see below), both tumor necrosis factor-a (TNF-a) and interferon-g (IFN-g) have been associated with negative regulation of hematopoietic progenitors (Jacobsen et al., 1992; Maciejewski et al., 1995; Zhang et al., 1995; Yang et al., 2005b) . Furthermore, it was recently shown that TNF-a through activation of Fas inhibits self-renewal of murine LTR-HSCs, bringing out TNF-a and Fas as major negative regulators of HSCs .
Smad signaling and specification of HSCs during development
The first signs of hematopoiesis in the developing mouse embryos are the formation of blood islands from extraembryonic mesoderm in the yolk sac at embryonic day 7.5 (E7.5) (Yoder, 2001 ). Blood islands are composed of primitive, nucleated erythrocytes surrounded by ECs. The close spatial and temporal occurrence of erythrocytes and ECs in the blood islands has led to the hypothesis that they have a common mesodermal precursor, the 'hemangioblast' (Mikkola and (Figure 4) . By E8-E8.5 precursors with definitive hematopoietic potential arise in the yolk sac as well as intraembryonically along the dorsal aorta in a region called para-aortic splanchnopleura, which later forms the AGM (Cumano et al., 1996; Medvinsky and Dzierzak, 1996; Yoder et al., 1997) . Shortly thereafter, hematopoiesis shifts to the fetal liver and around the time of birth the BM becomes the major site of hematopoiesis. The mechanisms that control the sequential induction of mesoderm, formation of the hemangioblast and commitment of hematopoietic precursors are still not well understood. An important tool to investigate these early specification events of HSCs, in addition to the study of embryos, has been the embryonic stem (ES) cell differentiation system. In the absence of leukemia inhibiting factor, ES cells will aggregate and form the so-called embryoid bodies (EBs) that are composed of all three germ layers. These can be differentiated further in a manner that mimics several aspects of normal embryonic development in utero, including formation of hemangioblasts from mesodermal precursors and the generation of primitive and definitive hematopoietic cells (Lacaud et al., 2001) (Figure 4) .
A large number of studies in several different species have implicated a key role of BMP4 in mesoderm induction and hematopoietic commitment (reviewed in Snyder et al., 2004) . For example, studies using Xenopus embryos and explant assays have demonstrated that BMP4 together with either basic fibroblast growth factor or activin A can induce the formation of red blood cells from non-mesodermal structures (Huber et al., 1998) . Furthermore, hematopoietic commitment induced by the GATA binding transcription factors GATA-1 and GATA-2 required intact BMP signaling (Maeno et al., 1996; Huber et al., 1998) . Mice lacking BMP4 die between E7.5 and E9.5 exhibit severe defects in mesoderm formation and the embryos that survive up to E9.5 show defective blood islands (Winnier et al., 1995) . Studies using differentiation of mouse ES cells support these findings as BMP4 induces the formation of mesoderm and hematopoietic precursors and inhibition of BMP signaling impairs hematopoietic development in this setting (Johansson and Wiles, 1995; Park et al., 2004) . In addition, it was recently demonstrated that BMP4, in combination with cytokines, promotes hematopoietic differentiation of human ES cells (Chadwick et al., 2003) . While BMP4 appears to have a crucial instructive role for the induction and formation of blood cell precursors, other factors may regulate their subsequent expansion. Vascular endothelial growth factor (VEGF) has been shown to mediate efficient expansion and differentiation of BMP4 induced hematopoietic progenitors (Park et al., 2004) . Interestingly, the VEGF effect is inhibited by TGF-b and augmented by activin A implicating these family members in the regulation of committed blood precursors during development (Park et al., 2004) (Figure 4) . The original studies of mouse embryos lacking TGFb1 demonstrated severe defects in the yolk sacs, including malformed vascular structures and an almost complete absence of red blood cells leading to death around E10 (Dickson et al., 1995) . The apparent lack of hematopoiesis in these embryos suggested a critical role for TGF-b1 in directing hematopoietic development during embryogenesis, a notion that was further supported from studies of TbRII-deficient embryos (Dickson et al., 1995; Oshima et al., 1996) . However, the mechanism behind the lack of hematopoietic cells was investigated in more detail using TGF-b signalingdeficient embryos lacking TbRI. In striking contrast to the severe yolk sac anemia, which was present also in these embryos, a large increase in numbers of erythroid colony-forming cells (CFCs) could be detected when yolk sac cells were assayed in vitro . These findings demonstrated that induction and commitment of hematopoietic precursors during development are intact in the absence of TGF-b signaling. Thus, in contrast to BMP4, TGF-b1 does not seem to be an important regulator of the earliest specification events of hematopoietic commitment. The increased numbers of erythroid progenitors suggested, however, that TGF-b has an inhibitory function in the early expansion of committed hematopoietic precursors which is consistent with the studies mentioned above using ES cell differentiation (Park et al., 2004) .
Blastula / ES-cell

Gastrulation / Embryoid body formation
The role of Smad5 in embryonic hematopoiesis has been studied using embryos and ES cells with targeted disruptions of the Smad5 gene. Disruption of the Smad5 gene in mice leads to a phenotype very similar to that observed in knockouts for the TGF-b receptors with severe defects in yolk sac circulation and subsequent death around midgestation Yang et al., 1999) . Yolk sacs from these embryos had increased numbers of high-proliferative potential colony-forming cells (HPP-CFCs) with enhanced replating potential (Liu et al., 2003) . Importantly, similar findings were also demonstrated in EBs derived from in vitro differentiated Smad5À/À ES cells (Liu et al., 2003) . These EBs had increased numbers of blast colonyforming cells (BL-CFCs), which are believed to be the in vitro equivalent of hemangioblasts in addition to a marked increased frequency of HPP-CFCs. These data suggest that Smad5 transduces signals that inhibit the early specification events of hematopoietic precursors as well as their subsequent expansion (Liu et al., 2003) . These findings are somewhat confusing since Smad5 is primarily thought to be involved in the BMP signaling cascade and BMP4 has quite an opposite role in this regard. However, Smad5-deficient HPP-CFCs displayed decreased sensitivity to TGF-b1 inhibition, suggesting a role of Smad5 in mediating TGF-b signals in this setting (Liu et al., 2003) . Furthermore, in another study, inhibition of Smad5 was shown to neutralize the inhibitory effects of TGF-b on primitive hematopoietic progenitors . Thus, Smad5 may be an additional mediator of TGF-b signaling in hematopoietic cells (apart form Smad2 and Smad3), but the potential mechanisms for this are not understood. It has been shown that Smad5 differs from the other BMP-regulated Smads (Smad1 and Smad8) in its DNAbinding abilities and more resembles the TGF-b-specific Smad3 in those aspects (Li et al., 2001) . The alternative TGF-b type I receptor, ALK1, can transduce TGF-b signals through Smad1, Smad5 and Smad8 in ECs (Roelen et al., 1997; Lux et al., 1999; Oh et al., 2000) . An intriguing possibility would be that the accessory receptor endoglin could play a role in this regard. Endoglin and ALK1 seem to mediate highly similar responses as mutations in the genes encoding either endoglin or ALK1 have been directly linked to a human disease called HHT, which is an autosomal dominant disorder, characterized by recurrent hemorrhages and vascular dysplasia in multiple organs (McAllister et al., 1994; Johnson et al., 1996) . While ALK1 is not expressed in HSCs (our unpublished observations), endoglin was recently shown to be selectively expressed in the most primitive fraction of hematopoietic cells (Chen et al., 2002) .
Smad signaling in adult HSCs
TGF-b signaling regulates multiple aspects of hematopoiesis and exerts a wide range of responses in cells at all differentiation stages of the hematopoietic hierarchy. Here, we have focused our discussion mainly on the role of TGF-b and Smad signaling in growth regulation of HSCs. For a detailed review on TGF-b signaling in hematopoiesis in general see Fortunel et al. (2000) .
TGF-b1 ligand stimulation of HSCs and progenitors
A critical role for TGF-b in the regulation of HSCs and progenitor cells was demonstrated more than 15 years ago. The original findings showed potent inhibition by TGF-b1 on the growth of early MPPs, while more mature progenitors were unaffected (Ohta et al., 1987; Keller et al., 1988) . A large number of studies on both human and murine cells have supported these original findings of potent growth inhibitory actions on early hematopoietic progenitors (Ottmann and Pelus, 1988; Sing et al., 1988; Keller et al., 1990; Jacobsen et al., 1991a) . However, the effects on more mature progenitor cells are complex and depend on the presence of other growth factors. For example TGF-b inhibits IL-3-induced granulocyte-macrophage (GM) colony formation, while GM-CSF-induced GM colony formation is stimulated (Ruscetti and Bartelmez, 2001 ). Thus, the effects of TGF-b in these in vitro systems are dependent on the differentiation stage of the target cells and the actions of other cytokines. Studies on purified murine HSCs showed that TGF-b inhibits the initial cell divisions of these cells demonstrating direct regulatory effects on HSCs (Sitnicka et al., 1996) . Similar direct inhibitory actions of TGF-b have also been demonstrated in purified human primitive progenitor cells (Garbe et al., 1997; Batard et al., 2000) . The effects of TGF-b on hematopoiesis have also been studied in vivo. TGF-b1 was injected into the femoral artery and potently inhibited multipotent hematopoietic progenitors in the BM (Goey et al., 1989) .
The mechanism of TGF-b action on hematopoietic progenitors is not fully understood, but the effects are in part due to modulation of cytokine receptors. TGF-b downmodulates expression of the receptors for IL-1, GM-CSF, IL-3, G-CSF and SCF (Dubois et al., 1990; Jacobsen et al., 1991b; Dubois et al., 1994) . The growth inhibitory effects by TGF-b are mainly thought to be exerted by cell cycle arrest. This is supported by findings demonstrating reversibility in the growth inhibitory actions of TGF-b, suggesting that TGF-b delays proliferation rather than exerting irreversible negative effects such as induction of apoptosis (Sitnicka et al., 1996; Batard et al., 2000) . However, a number of reports have shown involvement of TGF-b also in apoptosis of BM progenitors. In fact, both apoptotic and antiapoptotic effects of TGF-b have been described Veiby et al., 1996; Dybedal et al., 1997) . Thus, TGF-b may regulate growth of hematopoietic progenitors through effects on both cell cycling and apoptosis.
A relative drawback when interpreting effects of exogenous ligand stimulation involves the difficulty of ruling out toxic effects from very biopotent molecules like active TGF-b. The actions of TGF-b are known to be strongly contextual and it is possible that factors like the presence or absence of serum or the degree of cytokine stimulation used for in vitro culture may strongly affect the biological responses observed. Although soluble growth factors can be intravenously injected into mice to test also their in vivo functions, it is very difficult to control the concentrations and distribution of the growth factor or the efficiency of antibody neutralization. Interpretations of experiments involving injection of active TGF-b in vivo are also complicated by the fact that active TGF-b is a very potent growth factor with a short half-life and is generated from the more stable latent TGF-b form (Taipale et al., 1994) (Munger et al., 1997; Crawford et al., 1998; Fortunel et al., 2000) . Further, the levels and spatial distribution achieved from exogenous sources of active TGF-b could very well exert effects that are not relevant in the cells physiological context. Since practically all cell types, including those of hematopoietic origin, express TGF-b receptors, they are also likely to respond to exogenous TGF-b stimulation.
TGF-b ligand neutralization
The role of endogenous TGF-b has been investigated in several studies using TGF-b neutralizing antibodies or antisense oligonucleotides to block TGF-b signaling in vitro. Such treatment of early human hematopoietic progenitors releases these cells from quiescence and enhances the frequency of colony formation (Fortunel et al., 1998; Hatzfeld et al., 1991) . Similar effects have been demonstrated in the murine system. Culture of mouse BM cells in the presence of an anti-TGF-b antibody resulted in increased long-term in vivo repopulation ability of these cells, suggesting that interfering with TGF-b signaling may cause expansion of HSCs in vitro (Soma et al., 1996) . These studies have implied an important role of endogenous TGF-b signaling in maintaining quiescence of HSCs. The effects of TGF-b neutralization have further been evaluated in several studies using retroviral gene transfer to hematopoietic cells. Release from quiescence is a prerequisite for successful gene transfer with oncoretroviral vectors and a number of studies have demonstrated increased retroviral transduction efficiency of both murine and human primitive hematopoietic progenitors following neutralization of TGF-b (Hatzfeld et al., 1996; Imbert et al., 1998; Yu et al., 1998) . However, when evaluating results from such studies, a particular concern is the common use of high concentrations of serum in the culture medium. Indeed, when levels of latent and active TGF-b1 were quantified in serum used for hematopoietic cultures, significant levels of both forms could be detected (Dybedal and Jacobsen, 1995) . Thus, observed effects could at least partly be due to neutralization of exogenous TGF-b in the medium rather than blocked endogenous signaling. Therefore, experimental approaches involving loss of function may be preferred to determine the physiological role of a particular signaling pathway.
Genetic approaches for inactivation of TGF-b signaling in HSCs
While numerous in vitro studies have suggested a critical role of TGF-b in negatively regulating proliferation of hematopoietic stem-and early progenitor cells, the role of endogenous TGF-b signaling in hematopoiesis in vivo has until recently remained largely unknown. Although genetic manipulation of hematopoietic cells can be used effectively to study fate decisions in hematopoietic cells in vitro, genetic perturbation of Smad signaling offers a particularly promising approach to study the role of Smad pathways in the function and fate options of hematopoietic cells in vivo. Gain-of-function approaches can be used through retroviral transgenesis of BM cells followed by transplantation to restrict the phenotype to the hematopoietic system (Sauvageau et al., 1995) or through the use of transgenic mice overexpressing ligands, mutant receptors or Smads. Overexpression of the TGF-b ligands has been used to study liver fibrosis and kidney pathology (Sanderson et al., 1995) , but studies using overexpression of ligands can generate complex phenotypes because many effects are not cell autonomous. The regulation of T-cell development and function was effectively studied by targeting expression of a dominant-negative TGF-b receptor II to T cells in mice (Gorelik and Flavell, 2000; Lucas et al., 2000) . However, for studies of HSCs, overexpression in transgenic mice has been used to a quite limited extent mostly because good tissue-specific promoters for the HSC compartment are not available, and even if they were, they could cause a lethal phenotype during development and their use would then be limited to developmental hematopoiesis. Inducible systems have been developed to study genetic regulation of hematopoiesis (Bjornsson et al., 2001) , but this approach, while promising, has not been applied so far to study the Smad signaling pathway in hematopoietic development.
Lack-of-function studies using gene knockout mice may be the most accurate way to study the physiological role of a certain gene or regulatory pathway in vivo. However, conventional knockout models have some limitations. For example, knocking out genes that are important during development often results in embryonic or early lethality. This has been a common phenotype for many genes associated with stem cell regulation, like TGF-b and its receptors (Shull et al., 1992; Kulkarni et al., 1993; Kaartinen et al., 1995; Oshima et al., 1996; Sanford et al., 1997; Larsson et al., 2001) . Important insights into the role of TGF-b in regulating the immune system came from the TGF-b1 knockout mice (Shull et al., 1992; Kulkarni et al., 1993) . These animals exhibited two phenotypes: around 50% of the mice died during embryogenesis from failed yolk sac circulation as discussed above (Dickson et al., 1995) , while the others survived beyond birth, due to maternal transfer of TGF-b1 via the placenta (Shull et al., 1992; Kulkarni et al., 1993; Letterio et al., 1994) . Surviving mice developed a rapid wasting syndrome shortly after birth and died at an age of 3-5 weeks exhibiting massive inflammatory infiltrates (mainly lymphocytes and macrophages) and tissue destruction in several organs, particularly the heart and lungs. The early lethality and massive inflammatory response made it very difficult to carry out detailed studies of hematopoiesis and HSC function in the TGF-b1 knockout mice. The Cre/loxP conditional knockout system has become an important tool to bypass embryonic lethality and to direct a gene knock out to a certain tissue, cell type or time point during development and in the adult mouse (Sauer, 1998) . The success of this system is highly dependent on specific and efficient Cre delivery from transgenic mice. The IFN-inducible MxCre transgenic mouse has become a very useful tool for Cre delivery in the hematopoietic system because it expresses Cre in HSC upon induction with IFN (Kuhn et al., 1995; Horcher et al., 2001; Brakebusch et al., 2002; Gerber et al., 2002) . Thus, this system allows for accurate studies of steadystate hematopoiesis in adult mice or the behavior of HSCs under stress, for example, during recovery after BM transplantation or serial transplantation.
HSCs in conditional knockout mice for TGF-b receptors
The physiological role of TGF-b signaling in adult hematopoiesis has been assessed using conditional Cre/ loxP knockout mice for the TGF-b receptors I and II. By mating the animals to the inducible MxCre transgenic mice, the consequences of disrupted TGF-b signaling could be studied in adult hematopoiesis. As expected, since both TbRI and TbRII are believed to be necessary for TGF-b signal transduction, knockout induction of either TbRI or TbRII caused a complete block in TGF-b signaling and the phenotypes in these mice were indistinguishable (Leveen et al., 2002; Larsson et al., 2003) . The induction of receptor-knockout in adult mice lead to a lethal disorder by 8-10 weeks after induction, in many ways similar to the phenotype in TGF-b1-deficient mice (Leveen et al., 2002) . Histopathological examination showed multiple inflammatory lesions in several organs. Surprisingly, however, and unlike the TGF-b1 mice, BM from these receptordeficient animals, taken immediately after induction, caused inflammation and death by 6-9 weeks posttransplantation when transferred in limited numbers to normal C57BL/6 recipients. The findings demonstrated that TGF-b receptor-deficient cells of hematopoietic origin, most likely T cells, could induce multifocal inflammatory disease in a dominant manner (Leveen et al., 2002) . However, before the onset of disease all hematopoietic parameters were normal in the induced knockout mice . Transplantation of BM cells to the immune-deficient nude mice bypassed the inflammatory disease and provided a model to study the LT repopulation kinetics of knockout HSCs. Surprisingly, when the proliferation kinetics of TGF-b signaling-deficient HSCs were measured by competitive repopulation in this model, no difference compared to controls was observed, neither in primary nor in secondary recipients . The same applied when HSCs were further challenged under conditions of severe hematopoietic stress triggered by myeloablative treatment or serial transplantations (Larsson et al., 2005) . Thus, these experiments clearly suggested that endogenous TGF-b signaling does not play a critical role in regulating growth and maintenance of HSCs in vivo. This is in sharp contrast to the numerous reports demonstrating very potent effects of blocking TGF-b in these cells in vitro and could possibly be explained by differences in the experimental approach to interfere with TGF-b signaling: transient block using antibodies or antisense oligonucleotides versus permanent genetic deletion of the receptors. However, when TGF-b signaling-deficient HSCs from induced receptor-knockout mice were assayed in vitro with low cytokine stimulation (SCF alone), these cells had a significantly increased recruitment to proliferation, consistent with other in vitro studies. This suggests that differences in the in vitro and in vivo environment are the main reason for the different outcomes between these experimental settings. Cells in the hematopoietic microenvironment, including BM stromal fibroblasts, osteoblasts and ECs, present growth regulatory signals to HSC and play an important role for HSC regulation in the BM environment (Calvi et al., 2003; Zhang et al., 2003) (Figure 5 ). In addition, interactions between ECM components and membrane bound molecules on HSCs such as the integrins allow for adhesion and homing of circulating HSCs to the BM microenvironment (Potocnik et al., 2000) . These interactions are also thought to transduce signals to the intracellular space, and act to maintain the HSCs in a quiescent state (Krause, 2002) (Figure 5 ). Thus, there are numerous signaling entities in the in vivo microenvironment that are not present in standard in vitro culture systems. The extreme expansion potential of HSCs requires a tight regulatory network with backup mechanisms in order to minimize the risk of uncontrolled growth and differentiation. Crosstalk and compensatory mechanisms from other signaling pathways are therefore likely to be more pronounced in vivo and may very well explain the differences between our findings in vivo and those from in vitro studies. An important observation when the growth kinetics of knockout HSCs were studied in vitro under serum-free conditions was that increased proliferation recruitment of HSCs only was evident under low stimulatory conditions (SCF alone) and could not be observed when additional cytokines were added to the medium . This suggests that endogenous TGF-b signaling, in this experimental setting, only executes significant antiproliferative effects when positive acting signals are kept at low levels. The same phenomenon was seen when primitive human progenitors overexpressing a dominant-negative mutant of the TGF-b type II receptor were grown under similar conditions with varying cytokine stimulation (Fan et al., 2002) . Together, these observations demonstrate the context dependency of TGF-b signaling in HSCs and how activation of several signaling pathways can result in interference. It is not clear, however, whether this occurs at the level of intracellular signaling through specific crosstalk between signaling pathways or whether the cellular responses from positively acting signals simply dominate over the effects from inhibitory signals, in this case endogenous TGF-b signaling. Similar mechanisms could apply in vivo. The degree of cytokine stimulation within the BM compartment is highly dependent on the level of hematopoietic stress. Thus, under conditions requiring high demands on the hematopoietic system, such as the recovery from irradiation or cytotoxic treatment, the signals within the BM microenvironment are quite different than under normal steady-state hematopoiesis. Thus, the behavior of HSCs following transplantation as studied in the receptor-knockout mice may not be representative for normal steady-state conditions. It will therefore be important to create models where development and maintenance of TGF-b signaling-deficient HSCs can be followed over a long period of time under normal steady-state conditions with less stimulation.
The case of TGF-b2
The vast majority of studies of TGF-b signaling in hematopoiesis have specifically investigated the role of the TGF-b1 isoform. Although some in vitro studies have suggested inhibitory effects of TGF-b2 and TGFb3 on the growth of primitive progenitors, the roles of these TGF-b isoforms in the regulation of hematopoiesis have remained mostly unclear (Ohta et al., 1987; Ottmann and Pelus, 1988; Jacobsen et al., 1991a) . concentrations exerted stimulatory effects, while higher concentrations were inhibitory. Interestingly, the response to TGF-b2 was also determined by genetic background with extensive variation between mouse strains. A quantitative trait locus (QTL) was identified for the TGF-b2 effects on HSC proliferation that overlapped with a previously reported QTL-regulating HSC frequency (Langer et al., 2004) . Furthermore, frequency, proliferation and repopulation ability of HSCs in heterozygous knockout mice for TGF-b2 were lower compared to wild type, demonstrating the significance of the overlapping QTLs (Langer et al., 2004) . Thus, the findings suggest that TGF-b2, as opposed to TGF-b1, has an important role as a positive regulator of HSCs in vitro and in vivo. The distinct properties of TGF-b1 and TGF-b2 in the regulation of HSCs are puzzling and raise the question how their divergent responses are executed at the molecular level given the fact that the isoforms share significant sequence homology and signal through the same receptors. It has been shown that TbRII as well as the accessory receptors endoglin and betaglycan bind TGF-b1 and TGF-b2 with different affinities, which could help explain the intrinsically different effects of the two isoforms in HSCs (Cheifetz et al., 1992; LopezCasillas et al., 1993; Rodriguez et al., 1995) . However, the molecular mechanism behind the fundamentally different responses for the two isoforms and whether different Smads are involved in transducing their signals remains unknown.
The BMPs in adult hematopoiesis
Apart from the important role in specification of HSCs during development, described above, the BMPs and in particular BMP4 have been shown to regulate proliferation of adult HSCs. Treatment of highly enriched human HSCs (CD34 þ CD38 À Lin À ) with BMP2 and BMP7 inhibited proliferation similar to TGF-b1 (Bhatia et al., 1999) . However, using relatively high concentrations, BMP4 enhanced survival and increased the engraftment in nonobese diabetic-severe immunodeficiency (NOD/SCID) mice following ex vivo culture (Bhatia et al., 1999) . Thus, BMP4 may act as an important positive regulator of both proliferation and survival of HSCs. Interestingly, it was recently demonstrated that BMP4 signaling is important in mediating Shh-induced proliferation of primitive human progenitors (Bhardwaj et al., 2001) . Noggin, a specific inhibitor of BMP4, inhibited Shh-induced proliferation, but inhibition of Shh had no effect on BMP4-induced proliferation (Bhardwaj et al., 2001) . Similar associations between Shh signaling and BMP4 have been demonstrated in Drosophila. Both BMP and Shh represent pathways that are well conserved between embryonic settings and adult tissue stem cells as well as between different species, and it will certainly be an important task to further elucidate the molecular mechanisms behind the complex signaling crosstalk that occurs between these and other pathways.
Little is known about the in vivo role of BMPs in hematopoiesis mainly due to early lethality of knockout mice for the ligands and receptors. Conditional knockout mice for the BMP type I receptor, BMPRIA, revealed however, an important, yet indirect role of BMP signaling in regulation of HSCs by influencing the osteoblasts in the stem cell niche . The absence of BMPRIA caused increased numbers of HSC-supporting osteoblastic cells lining the bone surface, which in turn led to an increase in the numbers of HSCs in these mice . A role for BMP signaling in stress erythropoiesis in the spleen has recently been described (Lenox et al., 2005) Interfering with the entire Smad pathway Since Smad7 has been shown to block all Smad signaling pathways, enforced expression of Smad7 can be used to greatly reduce or eliminate Smad signaling in HSC. Recently, overexpression of Smad7 in human CD34 þ hematopoietic cells was found to augment myeloid differentiation at the expense of lymphoid commitment (Chadwick et al., 2005) . The Smad7 protein is produced in Lin À hematopoietic cells and Smad7 mRNA is expressed in purified LSKCD34 À murine HSC (unpublished observations). When BM cells overexpressing Smad7 are transplanted into irradiated recipients, the repopulation activity is increased, and upon serial transplantation, there is a significant increase in the regeneration of all hematopoietic lineages (Blank et al., 2004) . This demonstrates that enforced expression of Smad7 can increase self-renewal of HSC in vivo. In contrast, BM cells overexpressing Smad7 in a stroma-free ex vivo liquid culture do not exhibit increased proliferative capacity. Rather, the proliferation is reduced (Blank et al., 2004) . The findings indicate that a total block in Smad signaling increases selfrenewal of HSC in the BM microenvironment and that signaling crosstalk, perhaps mediated by the cells in the BM HSC niches, will increase self-renewal in Smad signaling-deficient HSC. These findings demonstrate that the outcome of HSC fate decisions mediated by all Smad signaling pathways is context dependent, as is seen with specific TGF-b signaling .
Involvement of TGF-b in hematopoietic malignancies
While alterations in TGF-b pathway genes have commonly been found in many epithelial neoplasms, for example, pancreatic cancer and colon cancer (Villanueva et al., 1998; Grady et al., 1999) , mutational inactivation involving the TGF-b signaling pathway is uncommon in leukemias and other hematological malignancies (reviewed in Kim and Letterio, 2003) . A potential role of TGF-b as a tumor suppressor has also been demonstrated in knockout mice. Heterozygous knockout mice for TGF-b1 get increased numbers of lung and liver tumors upon exposure to carcinogenic stimuli (Tang et al., 1998) and homozygous knockout mice for Smad3 live to adulthood, but spontaneously develop metastatic colorectal cancer, clearly supporting a role of the TGF-b signaling pathway in tumor suppression (Zhu et al., 1998) . In contrast, we have not been able to detect any signs of hematological malignancies in conditional knockout mice for TGF-b receptor I or transplanted BM recipients, where the knockout is induced in HSC just prior to transplantation . These findings suggest that deficient TGF-b signaling alone is not sufficient to induce neoplastic transformation in hematopoietic cells.
In an interesting recent study, the Smad3 protein could not be detected in fresh samples from patients with T-cell acute lymphocytic leukemia (ALL). The mechanism for the Smad3 deficiency is not known since the Smad3 mRNA was present and no mutations could be detected in the MADH3 gene (Wolfraim et al., 2004) . However, T-cell leukemogenesis was promoted in mice with haploinsufficiency of Smad3 that were completely deficient in p27
Kip1 (Wolfraim et al., 2004) . These findings are interesting because the p27
Kip1 gene is frequently mutated in pediatric ALL, due to translocations and deletions or germline mutation (Komuro et al., 1999; Takeuchi et al., 2002) . Impaired TGF-b signaling in hematologic malignancies can also be caused by suppression of Smad-dependent transcription responses by Tax, Evi-1 and AML1/ETO oncoproteins (Pietenpol et al., 1990; Kurokawa et al., 1998; Jakubowiak et al., 2000) . These findings agree with the notion that loss of TGF-b responsiveness in hematologic neoplasms is commonly caused by altered expression of Smad signaling coactivators or corepressors or due to mutations in TGF-b target genes (Kim and Letterio, 2003) . In contrast, primary mutations in TGF-b pathway genes, for example, in TGF-b receptors or Smad4, are rare in hematological malignancies, although single cases have been reported (Knaus et al., 1996; Schiemann et al., 1999; Imai et al., 2001) .
Stem cell expansion and development of cell therapy
Blood and marrow transplantation (BMT) is a wellestablished therapeutic modality to treat malignancies like leukemias and lymphomas and genetic disorders that affect the hematopoietic system. As it can be a challenge to find donors who have compatible histocompatibility antigens for the patients who need BMT, umbilical cord blood (CB) is used increasingly as a source of HSC due to the common availability of CB cells and the diversity of histocompatibility gene haplotypes that are available in the banked CB samples (Gluckman et al., 1989) . The number of HSC in each CB sample is limited and it would, therefore, greatly increase the applicability of this stem cell source if the CB stem cells could be expanded ex vivo prior to transplantation. Stem cell expansion can also theoretically be accomplished in vivo following engraftment of the transplanted cells, but this approach may involve more risks than ex vivo expansion unless the growth stimuli used in vivo can be carefully controlled (reviewed in Attar and Scadden, 2004; Sorrentino, 2004) . However, recent interesting findings suggest the possibility of increasing the number of stem cell niches in the BM microenvironment through alterations in BMP signaling. Mice with a conditional knockout of the BMPRIA receptor exhibit an increase in trabecular bone and an increase in the number of HSCs . The increased number and/or size of HSC niches was mediated through osteoblast-HSC contacts. Similarly, transgenic mice expressing parathyroid hormone in osteoblasts showed increased number of osteoblasts in trabecular bone and an increase in the size of the HSC pool through activation of the Notch pathway in HSC generated by the osteoblast-HSC association (Calvi et al., 2003) .
Stem cell expansion ex vivo will be easier to develop and involves fewer risks than in vivo expansion because the exact culture conditions can be controlled by defining the components in the media and transient modulation of regulatory pathways can be employed. However, even this approach is a challenge since successful stem cell expansion involves symmetric divisions of HSCs where the progeny cells are both HSC (Attar and Scadden, 2004) . More commonly, HSCs grown in vitro undergo asymmetric divisions where one HSC and a more differentiated progenitor is produced, or even worse, a symmetric division where both progeny cells have lost their HSC potential.
Since the transition from quiescence to proliferation of HSC is regulated by a balance between positive and negative regulators, the strategies for stem cell expansion should involve activation of regulators that encourage HSC self-renewal and inhibit pathways that mediate quiescence, differentiation or apoptosis of the HSC. The classical hematopoietic growth factors increase HSC survival and differentiation, but selfrenewal is only induced to a limited effect. Owing to the recent advances in understanding the mechanisms that control HSC self-renewal, novel approaches to expand stem cells can now be developed (Attar and Scadden, 2004; Sorrentino, 2004) . In order to accomplish this, several different signaling pathways, transcription factors and cell cycle regulators have to be simultaneously modulated to achieve the desirable effect ( Figure 6 ).
There is a potential role for modulation of Smad signaling to increase self-renewal of HSC and expand stem cells. The findings that BMP4 enhances proliferation of human HSC as described above indicate that BMP4 may be used in stem cell expansion protocols. Since TGF-b1 inhibits proliferation of primitive progenitors and perhaps HSC, antibodies against TGF-b1 have been used as a strategy to enhance HSC proliferation and engraftment of transplanted mouse recipients. Preliminary findings have suggested that antisense towards TGF-b can enhance the rate and absolute level of engraftment in mice (Bartelmez et al., 2000) , although the mechanism of the proliferative effect is not clear since TGF-b signaling-deficient HSC (that are deficient in signaling from all TGF-b isoforms including TGF-b2) do not exhibit increased proliferation in vivo . Interestingly, inactivation of TGF-b in serum-free medium did not enhance HSC proliferation without simultaneous downregulation of p27 (Dao et al., 1998) . However, there may be potential use for inactivation of this negative regulator in future clinical stem cell expansion protocols. It is not clear at present whether inactivation of other negative HSC regulatory cytokines like IFN-g or TNF-a may be useful for clinical stem cell expansion, but clear inhibitory effects of these factors have been demonstrated in murine HSC (Jacobsen et al., 1992; Maciejewski et al., 1995; Zhang et al., 1995; Bryder et al., 2001; Yang et al., 2005b) .
Modulation of Smad signaling pathways alone may not be sufficient to achieve effective stem cell expansion, but may be effective if used in concert with the activation of key positive regulatory pathways that promote HSC self-renewal. These include the transcription factor HoxB4 and the Wnt and Notch pathways. When HoxB4 is expressed in HSC ex vivo, over 40-fold net expansion of HSC was generated in 10-14 days (Antonchuk et al., 2002) . Further, modified HoxB4 proteins have been used successfully to stimulate proliferation of human and murine HSC ex vivo (Amsellem et al., 2003; Krosl et al., 2003) . The soluble form of the HoxB4 protein is actively taken up by HSC and can be used without concerns about insertional mutagenesis caused by HoxB4 retroviral vectors or the potential adverse effects that continuous production of HoxB4 in HSC might generate in vivo. Developmental cues that activate Notch and Wnt signaling in HSC may also be useful to increase HSC self-renewal ex vivo. Wnt3A can expand murine repopulating HSC and Wnt5A injection into NOD/SCID mice repopulated with human hematopoietic cells increased the reconstitution and number of primitive hematopoietic cells. Similarly, a soluble form of the Notch ligand, Jagged 1, can stimulate growth of human HSCs and may therefore be used to expand stem cells ex vivo (Karanu et al., 2000) .
The approaches described above involve the use of soluble proteins (or potentially matrix-fixed ligands, when required) to stimulate self-renewal of HSC and minimize differentiation since implementation of clinical stem cell expansion using these approaches is relatively straightforward provided that the proteins can be efficiently produced. Direct genetic modification can also be used using viral gene expression vectors to downregulate inhibitory pathways or for upregulation of pathways that stimulate self-renewal. Downregulation of CDKIs may be a feasible approach to increase proliferation and self-renewal of HSC. Downregulation of p21 in CD34 þ ,CD38 À human hematopoietic progenitors led to increased proliferation of primitive hematopoietic cells in vitro and in vivo (Stier et al., 2003) and HSC deficient in p18 exhibit increased selfrenewal in vivo (Yuan et al., 2004) . Viral vectors containing small interfering RNAs against p21 and p18 can be used to transduce HSC and may be able to release them from quiescence and increase proliferation and perhaps self-renewal divisions. Similarly, Smad7 vectors may be able to increase self-renewal of HSC in vitro if crosstalk pathways that help Smad7 to mediate the self-renewal effect in vivo can be identified and used in concert with enforced expression of Smad7. These approaches require viral vector-mediated gene transfer to HSC for efficient gene delivery. Ideally, the vectors should be nonintegrating and mediate transient gene expression for safety reasons (Baum et al., 2003; HaceinBey-Abina et al., 2003; Woods et al., 2003) . However, integrating vectors may be considered if the expression of the gene can be regulated upon demand (Bjornsson et al., 2001 ) and the vector design includes chromatin insulators and other safety-design features meant to minimize the risk of insertional oncogenesis (Baum et al., 2003) .
Effective stem cell expansion can only be achieved if multiple gene and signaling pathways are modulated in concert as described above for TGF-b and p27 (Dao et al., 1998) and the recent observation that p21 deficiency enhances the ability of HoxB4 to increase self-renewal (Miyake et al., 2004) . Figure 6 shows a schematic picture of how stem cells may be expanded in the future using modulation of many genetic pathways including signaling pathways, transcription factors and internal cell cycle regulators. It may even be possible to modify these genetic pathways with small molecule drugs that modulate gene expression as has been shown in the modulation of Wnt signaling and the expression of p21 and HoxB4 (Sato et al., 2004; Bug et al., 2005; De Felice et al., 2005) .
Conclusion
Smad signaling plays an important role in the regulation of hematopoiesis, both in the specification of HSCs and Modulation of stem cell signals to achieve stem cell expansion. Several different signaling pathways, transcription factors and cell cycle regulators will have to be simultaneously modulated to achieve efficient expansion 
